209808-06-0

Basic information

• Product Name: 1-BOC-4-(4-CHLORO-BENZOYL)-PIPERIDINE
• Synonyms: BIO-FARMA BF002995;1-BOC-4-(4-CHLORO-BENZOYL)-PIPERIDINE;tert-butyl 4-(4-chlorobenzoyl)piperidine-1-carboxylate
• CAS NO: 209808-06-0
• Molecular Formula: C₁₇H₂₂ClNO₃
• Molecular Weight: 323.81
• Mol File: 209808-06-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 437.443 °C at 760 mmHg
• Flash Point: 218.358 °C
• Appearance: /
• Density: 1.183g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-BOC-4-(4-CHLORO-BENZOYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(4-CHLORO-BENZOYL)-PIPERIDINE(209808-06-0)
• EPA Substance Registry System: 1-BOC-4-(4-CHLORO-BENZOYL)-PIPERIDINE(209808-06-0)

Safety Data

• Hazardous Substances Data: 209808-06-0(Hazardous Substances Data)

Usage

Description

1-BOC-4-(4-CHLORO-BENZOYL)-PIPERIDINE is a chemical compound that belongs to the class of piperidine derivatives. It is characterized by the presence of a benzoyl group with a chlorine atom at the para position, attached to the 4th carbon of the piperidine ring. 1-BOC-4-(4-CHLORO-BENZOYL)-PIPERIDINE is synthesized with a BOC (tert-butoxycarbonyl) protecting group, which is commonly used in organic chemistry to protect amino groups during various reactions.

Uses

Used in Pharmaceutical Industry:
1-BOC-4-(4-CHLORO-BENZOYL)-PIPERIDINE is used as a reactant for the structural optimization of 4-chlorobenzoylpiperidine derivatives. These derivatives are being developed as potent, reversible, and selective monoacylglycerol lipase (MAGL) inhibitors. MAGL is an enzyme that plays a crucial role in the degradation of endocannabinoids, which are involved in various physiological processes, including pain, inflammation, and mood regulation. By inhibiting MAGL, these derivatives have the potential to modulate the endocannabinoid system and may be useful in the treatment of various conditions such as chronic pain, neuroinflammation, and mood disorders.

InChI:InChI=1/C17H22ClNO3/c1-17(2,3)22-16(21)19-10-8-13(9-11-19)15(20)12-4-6-14(18)7-5-12/h4-7,13H,8-11H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 55695-51-7 4-(4-chlorobenzoyl)piperidine hydrochloride 
• 53220-41-0 4-(4-chlorobenzoyl)piperidine 
• 59084-15-0 N-acetyl-4-(p-chlorobenzoyl)piperidine 
• 59084-16-1 1-acetylpiperidine-4-carbonyl chloride 
• 25503-90-6 1-acetyl-piperidine-4-carboxylic acid 
• 639468-65-8 4-[(4-chlorophenyl)hydroxymethyl]piperidine-1-carboxylic acid tert-butyl ester 
• 160296-40-2 tert-butyl 1-[4-(4-fluorobenzoyl)piperidin-1-yl]carboxylate 
• 1046478-89-0 tert-butyl 4-(p-tolylsulfonylhydrazono)-piperidine-1-carboxylate 
• 104-88-1 4-chlorobenzaldehyde 
• 1517-47-1 p-chlorobenzaldehyde-d1 
• 1510865-53-8 tert-butyl 4-(2-((4-methoxyphenyl)sulfonyl)hydrazono)piperidine-1-carboxylate 
• 10359-09-8 2-(4-chlorophenyl)-1,3-dithiane 
• 99121-25-2 2-(4-Chlorphenyl)-2-deuterio-1,3-dithian 

Downstream Products

• 209808-08-2 4-(α-hydroxy-α-(4-N-tert-butoxycarbonylpiperidinyl)-4-chlororobenzyl)-N,N-diethylbenzamide 
• 639468-65-8 4-[(4-chlorophenyl)hydroxymethyl]piperidine-1-carboxylic acid tert-butyl ester 
• 209807-41-0 N,N-Diethyl-4-(4-chlorophenyl-piperidin-4-ylidene-methyl)-benzamide 
• 645379-32-4 1,1-dimethylethyl-4-[(4-chlorophenyl)carbonyl]-4-fluoro-1-piperidinecarboxylate 
• 885595-32-4 4-[amino(4-chlorophenyl)methyl]piperidine-1-carboxylic acid tert-butyl ester 
• 897630-52-3 C₁₇H₂₃ClN₂O₃ 
• 918502-07-5 C₁₉H₂₄ClN₃O₄ 
• 918501-97-0 C₁₉H₂₈ClNO₃ 
• 918501-90-3 C₂₀H₂₆ClNO₄ 
• 918501-89-0 C₂₀H₂₆ClNO₄ 
• 918501-81-2 tert-butyl 4-((4-chlorophenyl)(methoxy)methyl)piperidine-1-carboxylate 
• 42060-83-3 [1,1'-biphenyl]-4-yl(piperidin-4-yl)methanone 

Relevant articles and documents

MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS

The invention provides compounds of formula (I) or pharmaceutically acceptable salt thereof wherein ring A represents group A-I, A-II or A-III. Al represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A2 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A3 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A4 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A5 represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A6 represents -C(R4c)(R4c)- or -C(R4c)=; A7 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A8 represents -C(R4a)(R4a)-, -N(R4b)-, -O- or -S-; A9 represents -C(R4c)(R4c)- or -0-; A10 represents -C(R4c)(R4c)- or -0-; A11 represents -C(R4c)(R4c)- or -0-; A12 represents -C(R4a)(R4a)-, -O- or -S-; wherein group A-I, group A-II and group A-III de not contain adjacent oxygen atoms, adjacent oxygen and sulfur atoms or adjacent oxygen and nitrogen atoms or a moiety selected from the group consisting of N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S, wherein in each case the carbon atom in the N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S moiety is saturated; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a, R4b and R4c are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.

SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R22, R3, R4 and R5 are as defined in the specificatio

Preparation of unsymmetrical ketones from tosylhydrazones and aromatic aldehydes via formyl C-H bond insertion

Preparation of ketones by insertion of diazo compounds into the formyl C-H bond of an aldehyde is an attractive procedure, but use of structurally diverse diazo compounds is hampered by preparation and safety issues. A convenient procedure for the synthesis of unsymmetrical ketones from bench-stable tosylhydrazones and aryl aldehydes is reported. The procedure can be performed in one pot from the parent carbonyl compound and needs only a base, with no additional promoters being required.